![Figure 3. DVT model of electrolytic IVC injury. (A) Thrombus weight (TW) in IVC. (B) Platelet counts (PLT) in peripheral blood in mice with IVC injury. Platelet counts of nontreated control mice were not different among the groups (Pros1+/+, 118.4 ± 4.5 × 104/µL; Pros1+/E, 131.9 ± 13.1 × 104/µL; Pros1E/E, 110.5 ± 18.7 × 104/µL; Pros1+/−, 103.0 ± 14.5 × 104/µL; FvQ/Q, 111.9 ± 17.4 × 104/µL; mean ± standard error of the mean [SEM] of 3 mice). (C) TAT in plasma. TAT of nontreated control mice was not different among the groups (Pros1+/+, 3.2 ± 0.5 µg/L; Pros1+/E, 3.0 ± 0.3 µg/L; Pros1E/E, 2.7 ± 0.5 µg/L; Pros1+/−, 3.3 ± 0.8 µg/L; FvQ/Q, 3.5 ± 0.9 µg/L; mean ± SEM of 3 mice). (D) Interleukin-6 (IL-6) in plasma. IL-6 was not detected in nontreated mice of all genotypes (n = 3). Data are mean ± SEM of 12 mice for Pros1+/+, Pros1+/E, Pros1E/E, Pros1+/−, and FvQ/Q mice. *P < .05 in comparison with Pros1+/+ mice. **P < .001 in comparison with Pros1+/+ mice. †P < .001 in comparison with Pros1+/+ mice, and P < .05 in comparison with Pros1+/E mice.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/126/19/10.1182_blood-2015-06-653162/4/2247f3.jpeg?Expires=1722439534&Signature=tloDQk59iAKT0ENVSRlqcmzLaWsXmG-2LErGuUiFWtKtw7Bk8mRzZlZm4RDPFoNCkRfHZWmrzix13jAOl2J7gFMenyaIXL6cFJ7vkpZgm~jfyVE-SfujK7aa5GXzG1JZGqRB~dsAmgAky5LA3nQTwgTcaoOgCcKMvc1EPIVYdkDLbv8br7vD9hTMbhf~EDQq-y7SFZiCRvEzwut7M59Bp9OqrptysulR22T~d1qW8yVAx80wzXV-kXCKojpUVrKb51O55OTBlebtIsfbFoEGcKODfUifrvLsZJLT66ZSPCk631K~S1tNiUVvanbYj6G3lptf3vE5BI6BjKTwCe6zOA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
DVT model of electrolytic IVC injury. (A) Thrombus weight (TW) in IVC. (B) Platelet counts (PLT) in peripheral blood in mice with IVC injury. Platelet counts of nontreated control mice were not different among the groups (Pros1+/+, 118.4 ± 4.5 × 104/µL; Pros1+/E, 131.9 ± 13.1 × 104/µL; Pros1E/E, 110.5 ± 18.7 × 104/µL; Pros1+/−, 103.0 ± 14.5 × 104/µL; FvQ/Q, 111.9 ± 17.4 × 104/µL; mean ± standard error of the mean [SEM] of 3 mice). (C) TAT in plasma. TAT of nontreated control mice was not different among the groups (Pros1+/+, 3.2 ± 0.5 µg/L; Pros1+/E, 3.0 ± 0.3 µg/L; Pros1E/E, 2.7 ± 0.5 µg/L; Pros1+/−, 3.3 ± 0.8 µg/L; FvQ/Q, 3.5 ± 0.9 µg/L; mean ± SEM of 3 mice). (D) Interleukin-6 (IL-6) in plasma. IL-6 was not detected in nontreated mice of all genotypes (n = 3). Data are mean ± SEM of 12 mice for Pros1+/+, Pros1+/E, Pros1E/E, Pros1+/−, and FvQ/Q mice. *P < .05 in comparison with Pros1+/+ mice. **P < .001 in comparison with Pros1+/+ mice. †P < .001 in comparison with Pros1+/+ mice, and P < .05 in comparison with Pros1+/E mice.
